131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Annals of Oncology(2022)
Abstract
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with unresectable or metastatic disease. Standard first line chemotherapy is with gemcitabine and nab-paclitaxel, or FOLFIRINOX and median overall survival (OS) remains poor, under 12 months. The dense PDAC stroma acts as a barrier to drug delivery. CEND-1 is a novel cyclic tumor-penetrating peptide iRGD (internalizing arginylglycylaspartic acid) that may improve drug delivery by activating an endocytic/exocytic transport pathway by binding αvB3/5-integrins and downstream neuropilin-1.
MoreTranslated text
Key words
double-blinded,nab-paclitaxel,gastro-intestinal
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined